Advances in immunotherapy have led to durable and long‐term benefits in a subset of
patients across a number of solid tumor types. Understanding of the subsets of patients that …

Simple, efficient and well-tolerated delivery of CRISPR genome editing systems into primary
cells remains a major challenge. Here we describe an engineered Peptide-Assisted …

An improved understanding of the anti-tumor CD8+ T cell response after checkpoint
blockade would enable more informed and effective therapeutic strategies. Here we …

TCF-1 is a key transcription factor in progenitor exhausted CD8 T cells (Tex). Moreover, this
Tex cell subset mediates responses to PD-1 checkpoint pathway blockade. However, the …

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is
highly dependent on their differentiation status. It is now apparent that less differentiated T …

Use of immune checkpoint inhibitors targeting the programmed cell death protein-
1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

The immune system is a complex, dynamic, and plastic ecosystem composed of multiple cell
types that constantly sense and interact with their local microenvironment to protect from …

Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

Cytotoxic T cell immunity in response to chronic infections and tumours is maintained by a
specialized population of CD8+ T cells that exhibit hallmarks of both exhausted and memory …